2 0 0 0 OA バナナジュースはレボドパ製剤のバイオアベイラビリティを低下させる
- 著者
- 小合 由起 砂金 信義 太田 隆文 宇留野 強
- 出版者
- 公益社団法人 日本薬学会
- 雑誌
- YAKUGAKU ZASSHI (ISSN:00316903)
- 巻号頁・発行日
- vol.125, no.12, pp.1009-1011, 2005-12-01 (Released:2005-12-01)
- 参考文献数
- 2
- 被引用文献数
- 6 7
This study aimed to examine the effects of banana juice on levodopa bioavailability in rats. When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in Cmax (17.4±2.5 vs. 8.6±3.1 μg/ml; α=0.05) and AUC (1882.8±49.2 vs. 933.5±286.6 μg•min/ml; α=0.05) for levodopa. On the other hand, administration of the levodopa preparation with a commercial beverage containing 10% banana juice resulted in no significant change in Cmax or AUC. These results indicate that concomitant intake of levodopa preparations with banana juice, but not with a commercial banana beverage, may cause a drug-food interaction reducing levodopa bioavailability, and we should pay attention to such interactions during levodopa therapy for patients with Parkinson's disease.
2 0 0 0 OA バナナジュースはレボドパ製剤のバイオアベイラビリティを低下させる
- 著者
- 小合 由起 砂金 信義 太田 隆文 宇留野 強
- 出版者
- 公益社団法人日本薬学会
- 雑誌
- 藥學雜誌 (ISSN:00316903)
- 巻号頁・発行日
- vol.125, no.12, pp.1009-1011, 2005-12-01
- 被引用文献数
- 7
This study aimed to examine the effects of banana juice on levodopa bioavailability in rats. When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C_<max>(17.4±2.5vs.8.6±3.1μg/ml;α=0.05) and AUC(1882.8±49.2vs.933.5±286.6μg・min/ml;α=0.05) for levodopa. On the other hand, administration of the levodopa preparation with a commercial beverage containing 10% banana juice resulted in no significant change in C_<max> or AUC. These results indicate that concomitant intake of levodopa preparations with banana juice, but not with a commercial banana beverage, may cause a drug-food interaction reducing levodopa bioavailability, and we should pay attention to such interactions during levodopa therapy for patients with Parkinson's disease.